PSMA-targeted immune cell therapy for advanced solid tumors
Part of Cancer, Kidney & urinary clinical trials.
This study tests a special immune cell therapy (CAR-T cells) that targets a marker called PSMA found on some cancer cells. It is for patients whose cancer has not been stopped by standard treatments and who meet certain health and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has spread, recurred, or progressed after at least one standard treatment.
- Tests show your tumor cells have the PSMA marker.
- You are between 1 and 75 years old and weigh at least 10 kg (about 22 pounds).
- Your major organs (heart, lungs, liver, kidneys) are working well enough.
- No active, serious infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This trial tests a special type of cell therapy called CAR T cells. The cells are changed in the lab to find and attack a protein called CD276 on the surface of solid tumors. If the treatment works, your own immune cells could shrink the tumor or slow its growth.
This trial tests a new type of immune cell therapy that targets specific markers on breast cancer cells. It is designed for patients with advanced or relapsed breast cancer who have not responded to other treatments.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
This trial tests a type of immune therapy called CAR-T cells to treat autoimmune diseases. The treatment targets B cells, which are part of the immune system that can attack your own body in autoimmune conditions.
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.